AlzChem Group (ACT) Q3 2024 earnings summary

Executive summary

• Achieved strong Q3 2024 results, with group revenue up 4% to €415.2 million and EBITDA rising 36% to €76.8 million, driven by Specialty Chemicals now accounting for 62% of sales.

• Net income increased 66% to €39.1 million for the first nine months, with EPS up to €3.83.

• Major investments in nitroguanidine capacity expansion in Germany (€140 million) and a potential $150 million US grant, both largely grant-funded and pre-financed.

• Inclusion in the SDAX index and a Platinum Medal from EcoVadis for sustainability achievements.

• Share buyback program of up to €6 million and dividend payout of €12.2 million approved.

Financial highlights

• Q3 2024 sales reached €128.9 million, up 6.7% year-over-year; 9M sales at €415.2 million, up 4%.

• EBITDA for Q3 2024 was €24.9 million (up 27%), and for 9M 2024 €76.8 million (up 36%).

• Net income for 9M 2024 was €39.1 million, up from €23.6 million year-over-year.

• EPS for 9M 2024 rose to €3.83 from €2.31 year-over-year.

• Equity ratio improved to 40.1% as of September 30, 2024.

Outlook and guidance

• 2024 EBITDA expected to exceed €100 million, with margin above 17.5%.

• Sales outlook for 2024 confirmed but likely at the lower end of the forecast range (~€550–570 million).

• Revenue mix expected to shift further toward higher-margin Specialty Chemicals.

• Inventory and equity ratios expected to remain stable.

• All other performance measures remain in line with expectations.